Unaudited Financial results of the Company for quarter ended June 30, 2026.

Date: 05.08.2026 Department of Corporate Services, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 524748 Dear Sir/Madam, Sub: Outcome of Board Meeting held on 05th August, 2026. Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. 5th August, 2026, inter alia, considered and approved followings: 1. Unaudited Financial Results along with Limited Review Report for the quarter ended on 30th June, 2026. The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 with regard to change in Directors and Key Managerial Personnel are enclosed herewith Annexure. The meeting of the Board of Directors commenced at 12:15 p.m. and concluded at 02:00 p.m. Kindly take the same on your record. Thanking you, Yours truly, For Link Pharma Chem Limited Komal Bhojwani Company Secretary & Compliance officer Membership No.: A65594 REGISTERED OFFICE: Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India) Tel. (O) 9925057946 E-Mail: linkpharmacs@gmail.com CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in CNK & Associates LLP Chartered Accountants | Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Link Pharma Chem Limited 1. We have reviewed the accompanying Statement of Unaudited Financial results of Link Pharma Chem Limited (“the Company”) for the quarter ended 30t June, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and w Disclosure Requirement) Regulations, 2015, as amended (the “Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under | and other accounting principles generally accepted in India. Our responsibility is to express a \ conclusion on the Statements based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement. For CNK & Associates LLP Chartered Accountants Firm Registration No. 101961W/W-100036 Leatd reen Shah Partner Membership No. 125011 Place: Vadodara Date: 05t August, 2026 UDIN: 26125011EHQDBW8510 The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch’s Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483 Website: www.cnkindia.com VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | GURGOON | KOLKATA | BEENNGG.A LURU) || DEDELHLI HI || PPUUNNEE || DDUUBBAAII || AABB U DHABI Pharma Chem Ltd. LINK PHARMA CHEM LIMITED 1S0-9001-2015 - 1SO-14001-2015 - [SO-45001-2018 CIN: L24230GJ1984PLC007540 STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 s L Quarter ended Year ended " |particulars 30th 31st 30th 31st . lune March June March 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 |Revenue from operations Other income 876.84 658.88 781.48 2,743.15 Total Income (A) 34.89 14.7¢ 20.92 20.34 911.73 673.62 802.40 2,763.49 2 |Expenses: Cost of materials consumed pc rh a gn rg ee ss in ii nventories of ffiinniisshh ed goods and work-Kiinn-- 3 P78.00 2 Y10 8. 97 57 2 ¢69 1. 46 89 1,0 .61.76 Employee benefits expense oi pn wra een rcc ie a ln d amortization expense 1 215 749 ... 422 226 1 24 1 455 ... 520 197 1 2153 30. 940 102 6 S0 Other Expenses 79.11 66.83 86.36 32331 Total expenses (B) 81 75 28 .. 80 61 71 28 20 .. 62 20 71 54 16 .. 45 36 2,5 79 41 9. .5 92 3 |(Loss)/Profit before tax (C) = (A-B) 4 [Tax expense: 38.87 (49.00) 50.97 13.51 (1) Current tax (2) Deferred tax - - - - Total tax expense (D) 7.04 (8.14) 10.78 5.82 5 |(Loss)/Profit for the year/period (E) = (c-D) 37 1. 80 34 (4( 08 .. 81 64 ))] 41 00 .. 17 98 75 .. 68 92 6 |Other Comprehensive Income Items that will not be reclassified to profit or loss ON te ht e f ra i Cr ov ma pl ru ee hg ea ni sn io vn e e Iq nu cit oy m ei nstruments through (0.39) 0.29) 032 0.06 pR le am ne asurement (loss) / gain of the defined benefit ids 61 (o) o Income tax effect on above Total other comprehensive income for the (0.39) (2.18) 018 (1.68) vear/period, net of tax (F) [ & 3 & (o. 1 s) 5. 0 4 7 oT fo[T to Ttaa all x )c o (m Ep +Fr )e hheennssivie ve ii ncome for the year/perii od (Net $571 (3073) .03 1073 8 |Paid up Equity share capital of Rs 10 each 444.06 444.06 444.06 444.06 9 |Other Equity 834.86 10 |Earnings per equity share (FV of Rs. 10) (Rs.)(Not annualised) |___IBasic and pituted 072 (0.92) 091 017 REGISTERED OFFICE : Plot No. 162, G.LD.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), (India). Tel. (0) 99250 57946 E-Mail : linkpharmalimited@gmail.com CIN: L24230GJ1984PLC007540 www.linkpharmachem.co.in Pharma Chem Ltd. LINK PHARMA CHEM LIMITED 150-9001-2015 - 1SO-14001-2015 - ISO-45001-2018 Notes: 1 The above financial results for the Quarter ended on June 30, 2026 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 05, 2026. 2 The Company's operations fall under single segment namely “Manufacture and Sale of Chemicals" 3 As per the Ind AS 109 - ‘Financial Instruments’, the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder. Quarter ended Year ended 30th 315t 30th 31t Particulars June March June March 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) Other income (A) 34.89 14.74 20.92 2033 Fair value Net Gain/(loss) arising on financ [Showing first 8,000 characters — download PDF for full document]